ClinicalTrials.gg
TerminatedNCT00857818Updated Dec 2, 2013Results posted

Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome

A Phase 3 interventional study of Aripiprazole and Oanzapine, risperidone, or quetiapine in Schizophrenia, Schizoaffective Disorder and Bipolar I Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 14 sites in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2013-12-02.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Why this study was terminated
Slow Accrual

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
84th of 125
64 · median 130
Started
2009
with 2 others
Phase 3
34 of 126
1 open now
Registered
57th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 84th largest by enrollment of the 125 interventional ones that give a count, is one of 3 that started in 2009, is one of 34 in phase 3, and was the 57th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein (non-HDL) cholesterol levels with aripiprazole than with their current atypical antipsychotic treatment (olanzapine, risperidone, or quetiapine).

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder
  • Bipolar I Disorder
  • Metabolic Syndrome
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Competency in understanding nature of study and ability to sign form
  • A clinical diagnosis of schizophrenia, schizoaffective disorder, or bipolar I disorder (manic or mixed) that has been treated with antipsychotics (oral olanzapine, risperidone or quetiapine) for at least 3 months.
  • Treatment with any of the antipsychotic medications olanzapine, risperidone, or quetiapine for at least 3 months
  • A Clinical Global Impression-Severity Scale score of 4 or lower at baseline
  • Confirmed diagnosis of metabolic syndrome
  • Patients not receiving treatment specifically for any of the parameters related to metabolic syndrome at the time of randomization
  • Women of must be using an adequate method of to avoid pregnancy throughout the study and up to 4 weeks after last dose of product
  • Patients for whom it is clinically appropriate to switch from their current atypical antipsychotic to aripiprazole (determined by the investigator)

Exclusion criteria

Exclusion Criteria:

  • Risk of suicide (suicidal ideation or recently attempted suicide)
  • Meeting , 4th ed, text revision criteria for any significant psychoactive substance use disorder within 3 months of screening
  • Diagnosis of type 1 or 2 diabetes mellitus
  • Current treatment for 1 of the components of metabolic syndrome
  • Use of medication for the purpose of weight loss
  • Diagnosis of bipolar disorders other than bipolar 1, depression with psychotic symptoms, or organic brain syndromes
  • History of neuroleptic malignant syndrome
  • Diagnosis of Parkinson's disease, Alzheimer's disease, multiple sclerosis, cerebral palsy, epilepsy, or mental retardation
  • History of seizures
  • Abnormal blood count for , , absolute neutrophils, , alanine aminotransferase, creatinine, fasting glucose, and thyroid-stimulating hormone
  • recording with >475 msec
  • Detectable levels of cocaine or positive screen for stimulants or other drugs considered (determined by the investigator) to be of abuse or dependence
  • Blood alcohol levels superior or equal to 50 mg/dL [or 10.9 mmol/L]
  • Prior participation in an aripiprazole clinical trial
  • Treatment with aripiprazole within 1 month of enrollment
  • Predefined exclusionary laboratory tests
  • Patients with Bipolar Disorder treated with adjunctive therapy other than a stable dose of mood stabilizers (lithium or valproate) must undergo a 30-day for adjunctive therapies, such as antidepressants, prior to randomization.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Aripiprazole

    Drug: Aripiprazole

  • Active comparator
    Control group (Oanzapine, risperidone, or quetiapine)

    Drug: Oanzapine, risperidone, or quetiapine

Interventions

  • Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks

    Also known as: Abilify, BMS-334039

  • DrugOanzapine, risperidone, or quetiapine

    Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Levels

    Based on Last Observation Carried Forward data. Non-HDL cholesterol is defined as the difference between total cholesterol and high-density lipoprotein (HDL) cholesterol levels. Fasting non-HDL cholesterol is defined as the measured fasting HDL cholesterol level subtracted from the measured fasting total cholesterol level.

    Time frame: Baseline to Weeks 4, 8, and 16

  2. Mean Baseline Fasting Non-HDL Levels

    Time frame: At baseline (Day 1)

Secondary outcomes

  1. Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and 1 or More AEs

    AE=any new untoward medical event or worsening of a preexisting medical condition that may or may not be causally related to treatment. SAE=any untoward medical occurrence that at any dose results in death; is life-threatening, a congenital anomaly/birth defect, or an important medical event; requires or prolongs inpatient hospitalization, or results in persistent or significant incapacity or drug dependency or abuse.

    Time frame: Baseline to Week 16, continuously

  2. Mean Percent Changes From Baseline in Fasting Triglyceride and Total, High-Density Lipoprotein, and Low-Density Lipoprotein Cholesterol Levels

    Time frame: Baseline to Week 16

  3. Mean Changes From Baseline in Fasting Glucose Levels

    Time frame: Baseline to Week 16

  4. Percent of Participants Showing a Decrease or Increase in Body Weight of 7% or Greater From Baseline

    Time frame: Baseline and Weeks 4, 8, and 16

  5. Mean Changes From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

    The CGI-S scale is a 7-point scale that requires the clinician to rate the severity of a patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; or 7=extremely ill.

    Time frame: Baseline and Weeks 4, 8, and 16

  6. Number of Participants With Potentially Clinically Relevant Changes From Baseline in Blood Pressure, Heart Rate, Hemoglobin Levels, White Blood Cell Count, Differential Count, and Absolute Platelet Count

    Any value falling outside of the normal range will be flagged for the attention of the investigator at the site. The investigator will indicate whether or not a flagged value is of clinical significance.

    Time frame: Baseline and Weeks 4, 8, and 16

  7. Mean Change From Baseline in Impact of Weight on Quality of Life (IWQoL-Lite) Scores

    The IWQoL-Lite is a 31-item self-report survey that assesses the impact of weight on quality of life (QoL) in obese patients. Total score=the sum of scores(ranging from 1-5 for each item) for all 31 items. The sum is then rescaled to a 0-100 scoring, with 0 representing the poorest and 100 the best QoL. The survey also assesses improvements in QoL that occur with weight losses of 5% or greater and deteriorations in QoL with weight gain of 5% or greater. A change of 7.8 to 12.0 points from baseline=meaningful improvement. A change of -4.5 to -7.6 points from baseline=meaningful deterioration.

    Time frame: Baseline to Weeks 4, 8, and 16

  8. Mean Changes in Weight From Baseline

    Time frame: Baseline to Weeks 4, 8, and 16

  9. Median Changes in Body Mass Index From Baseline

    Time frame: Baseline to Weeks 4, 8, and 16

  10. Mean Changes in Serum Prolactin Levels From Baseline

    Time frame: Baseline to Weeks 4, 8. and 16

07

Results

Posted Jul 21, 2011
Limitations and caveats
The study terminated early due to low enrollment. Mean changes from baseline in: the Clinical Global Impression-Severity Scale and the Impact of Weight on Quality of Life scores were not analyzed due to insufficient data for meaningful conclusions.

Participant flow

Participant flow — Overall Study
MilestoneAripiprazoleControl Group (Olanzapine, Risperidone, or Quetiapine)
Started1414
Received treatment1412
Completed36
Not completed118
Withdrew: Lack of efficacy10
Withdrew: Adverse event30
Withdrew: Withdrawal by subject04
Withdrew: Sponsor terminated study64
Withdrew: Investigator decision10

Outcome measures

PrimaryMean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Levels

Based on Last Observation Carried Forward data. Non-HDL cholesterol is defined as the difference between total cholesterol and high-density lipoprotein (HDL) cholesterol levels. Fasting non-HDL cholesterol is defined as the measured fasting HDL cholesterol level subtracted from the measured fasting total cholesterol level.

Time frame:
Baseline to Weeks 4, 8, and 16
Reported as:
Mean · Percentage of change
Mean Percent Change From Baseline in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Levels
Percentage of changeAripiprazoleControl Group (Olanzapine, Risperidone, or Quetiapine)
Week 4-7.54 ± 3.220.19 ± 3.60
Week 8-18.45 ± 2.37-4.44 ± 2.86
Week 16-14.72 ± 3.86-2.47 ± 4.55
SecondaryNumber of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and 1 or More AEs

AE=any new untoward medical event or worsening of a preexisting medical condition that may or may not be causally related to treatment. SAE=any untoward medical occurrence that at any dose results in death; is life-threatening, a congenital anomaly/birth defect, or an important medical event; requires or prolongs inpatient hospitalization, or results in persistent or significant incapacity or drug dependency or abuse.

Time frame:
Baseline to Week 16, continuously
Reported as:
Number · Participants
Number of Participants With Death, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, and 1 or More AEs
ParticipantsAripiprazoleControl Group (Olanzapine, Risperidone, or Quetiapine)
Deaths00
SAEs20
AEs leading to discontinuation30
1 or more AEs116
SecondaryMean Percent Changes From Baseline in Fasting Triglyceride and Total, High-Density Lipoprotein, and Low-Density Lipoprotein Cholesterol Levels
Time frame:
Baseline to Week 16

No measurements were reported for this outcome.

SecondaryMean Changes From Baseline in Fasting Glucose Levels
Time frame:
Baseline to Week 16

No measurements were reported for this outcome.

SecondaryPercent of Participants Showing a Decrease or Increase in Body Weight of 7% or Greater From Baseline
Time frame:
Baseline and Weeks 4, 8, and 16

No measurements were reported for this outcome.

SecondaryMean Changes From Baseline in Clinical Global Impression-Severity (CGI-S) Scale

The CGI-S scale is a 7-point scale that requires the clinician to rate the severity of a patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness at the time of rating 1=normal, not at all ill; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; or 7=extremely ill.

Time frame:
Baseline and Weeks 4, 8, and 16

No measurements were reported for this outcome.

SecondaryNumber of Participants With Potentially Clinically Relevant Changes From Baseline in Blood Pressure, Heart Rate, Hemoglobin Levels, White Blood Cell Count, Differential Count, and Absolute Platelet Count

Any value falling outside of the normal range will be flagged for the attention of the investigator at the site. The investigator will indicate whether or not a flagged value is of clinical significance.

Time frame:
Baseline and Weeks 4, 8, and 16

No measurements were reported for this outcome.

SecondaryMean Change From Baseline in Impact of Weight on Quality of Life (IWQoL-Lite) Scores

The IWQoL-Lite is a 31-item self-report survey that assesses the impact of weight on quality of life (QoL) in obese patients. Total score=the sum of scores(ranging from 1-5 for each item) for all 31 items. The sum is then rescaled to a 0-100 scoring, with 0 representing the poorest and 100 the best QoL. The survey also assesses improvements in QoL that occur with weight losses of 5% or greater and deteriorations in QoL with weight gain of 5% or greater. A change of 7.8 to 12.0 points from baseline=meaningful improvement. A change of -4.5 to -7.6 points from baseline=meaningful deterioration.

Time frame:
Baseline to Weeks 4, 8, and 16

No measurements were reported for this outcome.

SecondaryMean Changes in Weight From Baseline
Time frame:
Baseline to Weeks 4, 8, and 16

No measurements were reported for this outcome.

SecondaryMedian Changes in Body Mass Index From Baseline
Time frame:
Baseline to Weeks 4, 8, and 16

No measurements were reported for this outcome.

SecondaryMean Changes in Serum Prolactin Levels From Baseline
Time frame:
Baseline to Weeks 4, 8. and 16

No measurements were reported for this outcome.

PrimaryMean Baseline Fasting Non-HDL Levels
Time frame:
At baseline (Day 1)
Reported as:
Mean · mg/dL
Mean Baseline Fasting Non-HDL Levels
mg/dLAripiprazoleControl Group (Olanzapine, Risperidone, or Quetiapine)
Mean Baseline Fasting Non-HDL Levels176.07 ± 13.76167.14 ± 14.01

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARIPIPRAZOLE—2/14 (14.3%)11/14 (78.6%)
CONTROL GROUP—0/12 (0%)6/12 (50%)
Most frequent serious events
Most frequent serious events
EventARIPIPRAZOLECONTROL GROUP
HALLUCINATION, VISUALPsychiatric disorders1/140/12
HALLUCINATION, AUDITORYPsychiatric disorders1/140/12
PSYCHIATRIC DECOMPENSATIONPsychiatric disorders1/140/12
NEUROLEPTIC MALIGNANT SYNDROMENervous system disorders1/140/12
Most frequent other events
Showing 10 of 33
Most frequent other events
EventARIPIPRAZOLECONTROL GROUP
INSOMNIAPsychiatric disorders3/140/12
TREMORNervous system disorders3/140/12
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations0/142/12
VISION BLURREDEye disorders2/140/12
ANXIETYPsychiatric disorders2/140/12
SOMNOLENCENervous system disorders1/141/12
NAUSEAGastrointestinal disorders1/141/12
ABDOMINAL PAINGastrointestinal disorders0/141/12
WOUNDInjury, poisoning and procedural complications0/141/12
PAIN IN JAWMusculoskeletal and connective tissue disorders0/141/12

Baseline characteristics

Age Continuous
Age Continuous(years)AripiprazoleControl Group (Olanzapine, Risperidone, or Quetiapine)Total
Mean39.0 ± 10.3632.9 ± 9.1035.9 ± 10.06
Sex: Female, Male
Sex: Female, Male(Participants)AripiprazoleControl Group (Olanzapine, Risperidone, or Quetiapine)Total
Female257
Male12921
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AripiprazoleControl Group (Olanzapine, Risperidone, or Quetiapine)Total
American Indian or Alaska Native011
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American101
White121224
More than one race000
Unknown or Not Reported000
08

Study locations

14 sites
  • Local Institution
    Calgary, Alberta T2N 2T9, Canada
  • Local Institution
    Pentincton, British Columbia V2A 4M4, Canada
  • Local Institution
    Vancouver, British Columbia V6T 2A1, Canada
  • Local Institution
    Hamilton, Ontario L8N 3K7, Canada
  • Local Institution
    London, Ontario N6H 4V1, Canada
  • Local Institution
    Markham, Ontario L6B 1A1, Canada
  • Local Institution
    Mississauga, Ontario L5M 4N4, Canada
  • Local Institution
    Toronto, Ontario M5T 1R8, Canada
  • Local Institution
    Toronto, Ontario M5T 2S8, Canada
  • Local Institution
    Montreal, Quebec H1N 3M5, Canada
  • Local Institution
    Montreal, Quebec H3A 1A1, Canada
  • Local Institution
    Montreal, Quebec H3M 3A9, Canada
  • Local Institution
    Montreal, Quebec H4H 1R3, Canada
  • Local Institution
    Quebec, G1R 2W8, Canada
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2009
First posted
Mar 9, 2009
Start
Apr 2009
Primary completionActual
Mar 2010
CompletionActual
Mar 2010
Results first posted
Jul 21, 2011
Last update
Dec 2, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00857818
First posted
Mar 9, 2009
Start date
Apr 2009
Primary completion
Mar 2010
Completion
Mar 2010
Results posted
Jul 21, 2011
Last update
Dec 2, 2013

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion